Dividends Inside 
Amgen Inc.
AMGN
$415.21 (- $2.63 - 0.63%)
Last updated: 2026-08-15 03:21 UTC
Amgen Inc. trades under ticker AMGN on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US0311621009, CUSIP 031162100. Also searched as Amgen.
Related researchAMGN stock priceAMGN share priceAMGN dividend historyAMGN dividend yieldAmgen dividend historyAmgen dividend yield031162100Amgen stockAmgen share price
About the Company
Amgen Inc. is a global biotechnology company that develops, manufactures, and commercializes human therapeutics for serious diseases. Its portfolio centers on biologic medicines and specialty therapies used in oncology, inflammation, cardiovascular disease, bone health, nephrology, and rare diseases. The company also markets biosimilars that provide alternatives to established biologic drugs, expanding its presence across major pharmaceutical categories. Amgen serves healthcare providers, hospitals, clinics, pharmacies, and wholesalers in markets around the world, with products distributed through both institutional and commercial channels. Its current business is built around discovering and delivering treatments that address high unmet medical needs, making Amgen a significant player in the biopharmaceutical sector and a key provider of advanced medicines within modern healthcare markets.
Price History
Latest News for AMGN
Romiplate Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
Market opportunities for Romiplate are driven by the increasing diagnosis of immune thrombocytopenia (ITP), expansion into additional thrombocytopenia conditions, strong commercial sales, global expansion, and growing physician adoption. These factors support its anticipated growth through 2034 in major global markets.Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "Romiplate Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report provides ins
How The Amgen (AMGN) Investment Story Is Shifting With New Guidance And Pipeline Updates
The latest fair value estimate for Amgen has shifted slightly, from US$350.03 to US$349.66, keeping modeled upside closely aligned with prior assumptions. That small adjustment fits with recent analyst commentary, where higher and lower price targets have been clustering around the current trading range as views on growth and execution remain mixed. As you read on, you will see how to track these changing signals and what they might mean for following Amgen’s evolving story over time. Stay...
Is It Time To Reassess Amgen (AMGN) After Strong Multi Year Share Price Gains
If you are wondering whether Amgen’s current share price reflects its true worth, starting with a clear look at what the market is paying for its fundamentals can help ground your view. The stock last closed at US$336.23, with returns of 2.2% over the past week, a decline of 4.2% over the past month, a 2.6% gain year to date and a 28.6% gain over the past year. The 3 year and 5 year returns sit at 64.4% and 56.2% respectively. Recent price moves sit against a backdrop of ongoing product...
Are Options Traders Betting on a Big Move in Amgen Stock?
Investors need to pay close attention to AMGN stock based on the movements in the options market lately.
Why the FDA’s push for real-time clinical trials could favor Big Pharma
The agency's new initiative promises faster drug approval times, but smaller trial sponsors could struggle to keep up.
Up 373%, Is ExxonMobil Proving Why It Was a Mistake for Salesforce to Replace ExxonMobil in the Dow Jones Industrial Average?
The Dow Jones Industrial Average would be even higher if it had more exposure to energy stocks.